Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 8 of 8 citing Lankas: Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes. (0.08 sec) 

GLP-1 and type 2 diabetes: physiology and new clinical advances


MMJ Combettes - Current opinion in pharmacology, 2006 - Elsevier
The first antidiabetic treatment (exenatide; Byetta) based on the incretin hormone glucagon-like
peptide-1 (GLP-1) was approved in 2005 as an adjunctive therapy in diabetic patients in whom
sulfonylurea, metformin or both had failed. Many GLP-1 mimetics or dipeptidyl peptidase ...
Cited by 15 - Related articles - All 3 versions

Diabetes mellitus in older men


MJ Kim, Y Rolland, O Cepeda, JK Gammack, JE … - The Aging …, 2006 - informahealthcare.com
Most persons with diabetes mellitus are over the age of 60 years. Males develop diabetes more
commonly than females. Older diabetics tend to have both impaired insulin release as well as
insulin resistance. In older persons diabetes mellitus is associated with decreased ...
Cited by 14 - Related articles - BL Direct - All 6 versions

Newly approved and promising antidiabetic agents


M Combettes, C Kargar - Therapie, 2007 - edpsciences. org
Abstract – Type 2 diabetes is an endocrine/metabolic disease characterized by
hyperglycemia. It is now well established that insulin resistance and pancreatic β-cell
dysfunction/failure are the two major components of the physiopathology of the disease. ...
Cited by 10 - Related articles - All 3 versions

Aromatic Heterocycle-Based DPP-IV Inhibitors: Xanthines and Related Structural …


BG Szczepankiewicz, R … - Current Topics in Medicinal …, 2007 - ingentaconnect.com
Abstract: Xanthines and xanthine-like DPP-IV inhibitors were first disclosed in 2002. Since
then, several dozen accounts of xanthine-based DPP-IV inhibitors have been published. Only
a few presentations and journal articles have appeared, with the vast majority of ...
Cited by 1 - Related articles - BL Direct - All 2 versions

Sitagliptin and Vildagliptin: Efficacy of Therapy in Type 2 Diabetes


JK Kirk, EC Oldham - Recent Patents on Endocrine, Metabolic &# …, 2008 - ingentaconnect.com
Page 1. 162 Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 2008,
2, 162-171 1872-2148/08 $100.00+.00 © 2008 Bentham Science Publishers Ltd.
Sitagliptin and Vildagliptin: Efficacy of Therapy in Type 2 Diabetes ...
Related articles

Medicinal Chemistry Approaches to the Inhibition of Dipeptidyl Peptidase IV


II Gwaltney, L Stephen - Current Topics in Medicinal Chemistry, 2008 - ingentaconnect.com
Abstract: Inhibitors of dipeptidyl peptidase IV (DPP-4) have emerged as an important new class
of therapeutic agents for type two diabetes. Various medicinal chemistry approaches have been
applied to this area and have resulted in the identification of numerous late-stage ...
Related articles - All 2 versions

Endogenous PYY and NPY mediate tonic Y1-and Y2-mediated absorption in …

- nih.gov
HM Cox - Nutrition, 2008 - Elsevier
Y 1 and Y 2 tones were present in human and WT mouse colon mucosa and only the latter was
TTX sensitive. Y 1 tone was unchanged in NPY −/− but was 90% inhibited in PYY −/− and abolished
in PYYNPY −/− colon mucosa. Y 2 tone was reduced 50% in NPY −/− and PYY −/− ...
Related articles - All 6 versions

Voir aussi…


N Approved, PA Agents - Thérapie, 2007 - ogst.ifp.fr
Abstract – Type 2 diabetes is an endocrine/metabolic disease characterized by
hyperglycemia. It is now well established that insulin resistance and pancreatic β-cell
dysfunction/failure are the two major components of the physiopathology of the disease. ...
Related articles - All 2 versions


 


Go to Google Home - About Google - About Google Scholar

©2009 Google